

Rett syndrome – biological pathways leading from MECP2 to disorder phenotypes

Friederike Ehrhart^{1,2}, Susan L.M. Coort², Elisa Cirillo², Eric Smeets¹, Chris T. Evelo^{1,2}, Leopold M. Curfs¹

¹ Governor Kremers Centre – Rett Expertise Centre, Maastricht University Medical Center, Maastricht, The Netherlands

² Department of Bioinformatics, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands

Corresponding author: Friederike Ehrhart, Maastricht University, Maastricht, The Netherlands, friederike.ehrhart@maastrichtuniversity.nl, ORCID [0000-0002-7770-620X](https://orcid.org/0000-0002-7770-620X)

Abbreviations: Rett syndrome (RTT), 5-methyl cytosine (5MeCyt), 5-hydroxy methyl cytosine (5OHMeCyt), induced pluripotent stem cells (iPSCs)

Genes, transcripts and proteins are abbreviated according to the human genome name consortium.

Keywords: Rett syndrome, MECP2, systems biology, bioinformatics, DNA methylation, epigenetics

Abstract

Rett syndrome (RTT) is a rare disease but still one of the most abundant causes for intellectual disability in females. Typical symptoms are onset at month 6-18 after normal pre- and postnatal development, loss of acquired skills and severe intellectual disability. The type and severity of symptoms are individually highly different. A single mutation in one gene, coding for methyl-CpG-binding protein 2 (MECP2), is responsible for the disease. The most important action of MECP2 is regulating epigenetic imprinting and chromatin condensation, but MECP2 influences many different biological pathways on multiple levels. In this review the known changes in metabolite levels, gene expression and biological pathways in RTT are summarized. It is discussed how they are leading to some characteristic RTT phenotypes and identifies the gaps of knowledge, namely which phenotypes have currently no mechanistic explanation leading back to MECP2 related pathways. As a result of this review the visualization of the biologic pathways showing MECP2 up- and downstream regulation was developed and published on [WikiPathways](https://www.wiki-pathways.com/).

1 Introduction

Rett syndrome (RTT; [MIM:312750](#)) occurs in 1:10.000 girls at the age of 12 (1). It is considered a rare disease since it affects fewer than 1 in 2000 individuals (2), but it is still one of the most abundant causes for intellectual disability in females. RTT was first described in 1966 by the Viennese pediatric Andreas Rett, who observed the typical hand movements (“hand washing”) of his patients (3, 4). Cause of RTT is in most cases a *de novo* mutation of [MECP2](#) (methyl-CpG-binding protein 2) gene; which was discovered by Amir et al. (5). However, as stated by Neul et al., “not all mutations in *MECP2* cause RTT and not all RTT patients have mutated *MECP2*”. Mutations in two other genes can also cause a RTT like phenotype, i.e. *FOXP1* and *CDKL5*, this was formerly considered as RTT but is now defined as RTT like syndrome (6).

RTT was considered a neurodevelopmental disorder but since some of the main symptoms were found to be reversible (7) researchers and clinicians tend to categorize it as a neurological disorder now (8). RTT was classified as an autism spectrum disorder before but not anymore. Patients often develop autistic features like social withdrawal but only during a certain stage of development (9). Although RTT has some autistic features/phases these usually disappear with time and adult RTT females are quite socially active again (10). *MECP2* mutations are rarely found in autism patients and if, they are termed “Autism with *MECP2* mutation” (6).

In this review, we summarize the knowledge about the *MECP2* gene and protein and discuss how they cause RTT phenotypes. In addition, the current insights in the downstream regulation activity of *MECP2* in RTT females will be discussed. This review integrates database knowledge from [Ensembl](#), [OMIM](#), [UniProt](#), [The Human Protein Atlas](#), and [Gene Ontology](#) and a biologic pathway was developed and published on [WikiPathways](#) to visualize the mechanistic action of *MECP2*.

2 Rett syndrome phenotype and diagnosis

Clinical diagnosis of RTT requires the following symptoms: decreased, arrested and retarded development of motoric and communication skills after 6-18 months of normal postnatal development, development of stereotypic movements and loss of purposeful movement. Although the onset of typical disorder symptoms after the age of 6 months is characteristic for RTT, observations of parents that “something is wrong with this child”, are often made before. RTT females are typically severely intellectually disabled, suffer under microcephaly and seizures. Additionally, they often develop symptoms like cardiac and breathing abnormalities, low muscle tension, autistic like behavior, scoliosis (and other osteopathies), sleeping problems and hormone disequilibrium (summary in Table 1). Typical noticeable laboratory results are EEG (and EKG) abnormalities, atypical brain glycolipids, altered neurotransmitter, creatine and growth factor levels, and alkalosis. Most of the symptoms can be related to disturbed neuronal function but some of them are caused or influenced by alterations which are not yet elucidated (4, 11, 12). It is also unknown whether it is the often in RTT observed changes of carbondioxide metabolism that cause respiratory problems or that dysfunctional brain stem neurons are responsible for breathing abnormality (4).

Table 1: Diagnosis criteria and characteristic symptoms of RTT*

Diagnosis criteria	• Arrested development between 6-18 months • Regression and loss of acquired skills • Loss of speech • Stereotypic movements • Gait abnormalities
Typical additional symptoms	• Cardiac abnormalities • Low muscle tension/hypotonia/ dystonia causing e.g. incontinence, constipation, chorea, bruxism, ataxia, spasticity • Impaired, autistic like social behavior: avoidance of eye contact, lack of social/emotional reciprocity, impaired use of nonverbal behavior, screaming fits, inconsolable crying • Breathing abnormalities • Consequences of mal/undernutrition(?): short stature, osteopathy, vitamin D deficiency, skoliosis • Sleeping problems • Hormone disequilibrium, e.g. thyroid hormones • Microencephaly • Seizures • Intellectual disability
Noticeable laboratory results	• EEG abnormalities • Atypical brain glycolipids • Elevated CSF levels of beta-endorphin and glutamate • Reduction of substance P • Decreased level of CSF nerve growth factors (BDNF) • Abnormal creatin levels • (Respiratory) alkalosis • Smaller and more densely packed neurons • Shorter, less complex and less dendritic spines

*Source: [OMIM#312750](#)

3 MECP2 gene, transcript and protein

The *MECP2* gene is highly conserved in Euteleostomi (bony vertebrates). The [NCBI HomoloGene/UniGene](#) database gives detailed information about gene homologues in 10 mammalian, 2 amphibian and 1 bony fish species (13). The human *MECP2* is located on chromosome X, position 154,021,573-154,137,103 (reverse strand) (according to Ensembl, version 84, genome build GRCh38.p5 (GCA_000001405.20)) and there are currently 21 transcripts known, two of these are protein coding (Figure 1). Due to dosage compensation *MECP2* is inactivated in one X-chromosome in females and the degree of inactivation is assumed to contribute to the difference in phenotypes for RTT (14). RTT is due

to its location on the X-chromosome more often observed in females. Hemizygous males with a severe mutation are generally not viable, but there are several non-lethal mutations which can lead to severe congenital encephalopathy, RTT-like syndrome, and mild to severe intellectual disability in males (15). Mosaic expression with only wild-type *MECP2* active in females are possible but supposed to be extremely rare (14).




Figure 1 *MECP2* gene and protein. *MECP2* gene is about 10505 bp long and has 4 exons. The protein has 486 amino acids and consists of 6 distinct domains whereas the methyl-DNA binding (MDB) and the transcriptional repression domain (TRD) are the most important for function.

The transcription and translation of *MECP2* is highly regulated (16) (Table 2 and Figure 2). There are several cis- and trans-regulatory elements for *MECP2* gene expression regulation known. Cis regulatory elements, including promotor elements, are loci on the DNA which act as binding sites for transcription factors and activate or repress gene expression. Trans-elements affect the regulation in an indirect way and can be located close or far away. They can for instance include genes that encode transcription factors for this specific gene. Translation of *MECP2* can be regulated by a set of microRNAs (17-25). MicroRNAs are small non-coding RNAs, that repress translation mRNA into protein by binding to the 3' untranslated region of the mRNA. The regulation of *MECP2* expression, stimulation and repression, is visualized in Figure 2 (transcriptional and translational regulation of *MECP2*) which is derived from [WikiPathways](http://www.wiki-pathways.com).

Table 2: Regulation of *MECP2* expression by transcription factors and microRNA

Type	Transcription factors/microRNA
Transcription factors targeting <i>MECP2</i> cis-elements (17-19)	Activation by BRN3, MYT1, SP1, SP3, C/EBP, CTCF, E2F1, TAF1, TAP1
	Repression by REST, BRN2, BCL6,
Trans-regulatory elements of <i>MECP2</i> (20)	Activation by HNRNPF
	Repression by HNRNPH1
miRNA (posttranscriptional repression) (21-25)	hsa-miR-483- 5p, hsa-miR-132-5p, hsa-miR-152-3p, hsa-miR-199a-3p, hsa-miR-30a-3p, and hsa-miR-130b-3p




Figure 2 MECP2 pathway from WikiPathways ([wiki-pathways.org/instance/WP3584](http://www.wiki-pathways.org/instance/WP3584)). Visualization of MECP2 being regulated by several upstream elements, e.g. promotor elements and microRNAs, and MECP2 regulating the expression and splicing of several downstream transcripts, proteins and miRNAs.

The two coding transcripts are isoforms of MECP2, long e1 and short e2, while e1 seems to be the more important one (26, 27). Itoh et al. observed that specific deactivation of e2 did not influence normal neurodevelopment while loss of e1 led to RTT (28). The MECP2 protein has at least six biochemically distinct domains (29). Two of them are most important for the protein function: the (84 amino acids) methyl-CpG binding domain (MDB) which is the one which selectively binds 5MeCyt and the transcriptional repression domain (TRD) (102 amino acids) which binds cofactors attracting histone deacetylase and finally leading to transcription repression as explained in the chapter 4 (Figure 1) (29, 30). Interestingly, MBD is the only structured domain (α -helix) while 60% of MECP2 is unstructured (29). For visualization of the structure see PDB (Protein Databank in Europe) (MECP2 ID: [3c2i](https://www.rcsb.org/structure/3c2i) and [1qk9](https://www.rcsb.org/structure/1qk9)) and the [Interpro ID](https://www.ebi.ac.uk/interpro/entry/IPR017353) is IPR017353.

MECP2 protein is most abundant in brain but also enriched in lung and spleen tissue (31). However, according to the [human protein atlas](https://www.proteinatlas.org/ENSG00000187633-MECP2) MECP2 protein (and its transcript) is found in almost every tissue. The cell type with the highest expression level is neurons, but MECP2 expression is also high in glial cells, astrocytes and oligodendrocytes where it influences specific gene expression (see Figure 2, effects on specific cells). In neurons an expression level of about 1.6×10^7 protein copies per nucleus was estimated by Skene et al. It is about the same number as nucleosomes or 5-methyl-cytosine (5MeCyt) spots on the DNA, leading to the suggestion that every spot might be covered by one MECP2 (32).

4 MECP2 function

MECP2 is a multifunctional protein which influences gene expression and metabolism on many levels (8) (Figure 3). The main function of MECP2 is to recognize and bind specifically methylated cytosine residues in the DNA (namely 5MeCyt) that are enriched with A/T bases adjacent (33). MECP2 binds also but with lesser affinity to hydroxymethylated DNA (namely 5-hydroxy methylated cytosine, 5OHMeCyt). Mutations in MECP2, which lead to loss of specific 5MeCyt binding functions are known to cause RTT (34).

This is in line with the Gene Ontology classification for the main molecular functions of MECP2: DNA binding, namely double-stranded methylated DNA and protein binding, namely histone deacetylase. The actual full Gene Ontology annotation of MECP2 can be found online e.g. [Ensembl database MECP2 entry](#).




Figure 3 MECP2 and its different levels of influence to chromatin structure, DNA binding, protein and metabolite level leading to clinical phenotypes. 5MeCyt = methylated cytosine, 5OHMeCyt = hydroxylated cytosine.

The molecular functions of MECP2 are known to influence various biological mechanisms, which are summarized and visualized in the pathway Figure 2, namely 1) MECP2 influences global translation by enhancing the AKT/mTOR signaling pathway (35), 2) Alternative splicing of downstream gene products is affected because MECP2 forms a complex with [YB1](#), an important splicing factor (19, 36-40), 3)

Expression of various microRNAs and long non-coding RNAs is regulated by MECP2 (20, 45, 47-49), and 4) MECP2 triggers the chromatin compaction at methylated DNA sites which regulates the transcription of adjacent genes (34, 37-41). The last one is an important (and best investigated) pathway and will be explained in detail below.

5 MECP2 as epigenetic regulator

Methylation of DNA is part of epigenetic gene expression regulation, where DNA is modified without changing the genetic code. Most transcription factors are unable to bind to methylated DNA so methylation usually silences a gene. Furthermore, methylated DNA is – via MECP2 mediated cofactor binding - a binding site for histone deacetylase (HDAC) which increases DNA compaction by removing certain acetyl residues from lysine at the histone tail allowing them to get closer to each other (Figure 2, MECP2-HDAC complex). So, methylated DNA is tightly wrapped around histone proteins and the access of transcription factors is physically inhibited (30). About 1% of DNA is methylated in humans and the methylation sites are often in regions with a high occurrence of CG, so-called CpG islands. CpG islands are present in the promotor regions of most human genes (60%). Methylation patterns play a role in cellular differentiation and tissue specific gene expression already during early development (41-43). The methylation pattern is continuously modified during mitosis and as part of DNA repair mechanisms and correct patterns needs to be maintained throughout life to grant cellular function (44, 45). Figure 4 visualizes the circular pathway of DNA methylation, hydroxylation and de-methylation and shows the mode of action of involved proteins and metabolites.




Figure 4 Pathway of cytosine methylation. The biological process is available at [wikipathways.org/instance/WP3585](http://www.wikipathways.org/instance/WP3585).

MECP2 recognizes and binds specifically to 5MeCyt present in DNA. After binding it attracts co-repressor complexes containing SIN3A, NCOR and SMRT. This co-repressor complex finally recruits histone deacetylase (HDAC) (19, 30, 36, 46) (Figure 2, see MECP2 – HDAC complex). The complex acts by removing certain acetyl groups from histone proteins leading to chromatin condensation around methylated DNA (47, 48). Cell culture experiments with an inhibitor of HDAC resulted in the same phenotype as MECP2-KO cells (49). The NCOR-SMRT interaction domain (NID) of MECP2 is located within the TRD domain and the association with NCOR-SMRT is responsible for transcription repression activity of MECP2.

MECP2 was generally considered as a transcription inhibitor but recent research found also a conditional transcription activation function. Skene et al. identified MECP2, because of its mere amount, being equal to number of histone octamers or methylated DNA sites, as a global damper of gene transcription in mature mouse brain cells (32). During MECP2 absence H3 (histone family 3) acetylation levels were globally elevated and H1 (histone family 1) levels doubled suggesting MECP2 alters global chromatin state towards condensation and represses transcription. Li et al. on the other hand found global transcription activation by MECP2 in human embryonic stem cells which underwent differentiation to neuronal cells but repression by MECP2 in mature neuronal cells indicating that MECP2 can be both, an activator and repressor (50). The activation mechanism is explained as follows: MECP2 recruits CREB1 as a cofactor to target gene promoters (51) (Figure 2, Activation of transcription). MECP2 binding to 5OHMeCyt was even interpreted as a marker of active genes in neurons (51). MECP2 was also found to form a TET1 containing complex which leads to 5MeCyt hydroxylation and further to demethylation of

DNA, enabling transcription (52). This mechanism was found to activate expression of downstream genes, namely BDNF, SST, OPRK1, GAMT, GPRIN1, and CREB1 (18) and is contradictory to other findings which describe MECP2 to block DNA demethylation by TET complex (Figure 4) (53).

MECP2 is additionally responsible for neuronal activity triggered transcription. Neuronal membrane depolarization and Ca^{2+} influx leads to phosphorylation of MECP2 which makes it detach from DNA, allowing decondensation and transcription (Figure 2) (54-58). Specific blocking of MECP2 phosphorylation sites led to RTT like symptoms (59).

6 Mutations of *MECP2* leading to RTT

At the moment, several hundred different mutations have been reported leading to RTT by loss or impaired function of MECP2 protein due to truncation, abnormal folding, or binding instability (15). This contributes to the variety of RTT phenotype and symptom severity.

The effects of total absence of MECP2 protein were investigated in several model systems. Deletion of *MECP2* from glial cells had only mild phenotypic consequences (60). In a mouse model specific deletion of *MECP2* in the forebrain caused behavioral abnormalities, limb claspings, impaired motor coordination, anxiety, and abnormal social behavior but not locomotor activity or changes in fear conditioning (61). In another mouse model, silencing MECP2 in GABAergic neurons led to severe RTT like phenotype (62).

67% of all *MECP2* mutations found in humans of are in eight hot spots: R106 (corresponding RS number from dbSNP: rs28934907), R133 (rs28934904), T158 (rs28934906), R168 (rs61748427), R255 (rs61749721), R270 (rs61750240), R294 (rs61751362) and R306 (rs28935468). Most of the mutations which cause RTT occur in the MDB region of *MECP2* (59). A 100fold reduction of binding affinity of MECP2 to methylated DNA is documented for the mutations R106W (rs28934907), R133C (rs28934904), and F155S (rs28934905) and binding affinity reduction of about 2fold was found in mutation T158M (rs28934906) (34).

7 The most important metabolites, genes and pathways affected by MECP2 in RTT

The examination and investigation of RTT females (and model systems) revealed that an impaired MECP2 influences biological pathways on many levels. Several genes have been found to be increased or decreased in expression, levels of various metabolites are changed and several biological pathways were found to be typically affected. In this chapter the main metabolites, genes and pathways which are influenced or changed by RTT are summarized. For getting these results, samples from human RTT females were often used but many results come from studies with *Mecp2*^{-/-} mice (e.g. the Bird model (63)). These mice do not express *Mecp2* at all and they display the same symptoms as humans, such as normal development until about 6 weeks, regression, reduced movement, clumsy gait, irregular breathing, and the mice have a reduced life span of about 3 months. Postmortem analysis revealed reduced brain and neuronal cell size which is similar to observations in humans. Other mouse strains or *in vitro* models with mutated MECP2, reduced or overexpressed MECP2 levels are also commonly used

to study RTT. Recently, researchers started to use iPSCs (induced pluripotent stem cells) from human or murine origin (64).

Metabolites

RTT syndrome was originally named cerebroatropic hyperammonemia, indicating that one of the first measurable findings was an increased level of ammonium in blood (3). Early autopsies revealed reduced levels of catecholamines, namely dopamine, serotonin and norepinephrine while markers for bioaminergic metabolism in general were higher (65, 66) (summary of metabolites in Table 3 and see also the list of metabolites on wiki.pathways.org/instance/WP3584). This was confirmed by a study of Panayotiset al. (67) who revealed time-dependent levels of dopamine, norepinephrine, serotonin, and their catabolites in the brain tissues of *Mecp2*^{-/-} mice. Viemari (68) et al. showed that *Mecp2*^{-/-} mice have a deficiency in norepinephrine and serotonin content in the medulla and a drastic reduction of medullary TH (catecholamine producing) neurons indicating that dysfunctional neuronal development may be the reason for decreased catecholamine levels. The phosphorylation of MECP2 is triggered by neuronal activity which is caused by release of neurotransmitters (Figure 2). Hutchinson et al. (69) demonstrated that phosphorylation of MECP2 is dependent on dopamine, serotonin and norepinephrine activated pathways (Figure 2, MECP2 phosphorylation).

Another metabolite shown to be present in high levels in RTT females is glutamate. Increased glutamate production (or decreased glutamate consumption) may lead to over excitation of glutamatergic neurons and can trigger increased uptake and conversion of glutamate to glutamine. Over excitation feedback may cause the downregulation of the glutamate receptor which was observed before (70). Moreover, severe downregulation in gene expression for the glutamate D1 receptor GRID1 (GluD1) was found (Figure 2). This receptor links post and presynaptic compartments and influences not only synopsis function but also neuronal differentiation (71). Glutamate levels during sleep-wake cycle were also affected in *Mecp2* deficient mice (72). Additionally, BDNF, which is directly regulated by MECP2, is also known to regulate GRID1 expression (73). Glutamate disposal is energy consumptive which may help explain the increased level of energy metabolism found in brains of *Mecp2*^{-/-} mice and RTT females in neuroimaging studies (74).

A metabolomics investigation found changed phospholipid profiles in *Mecp2*^{-/-} mice (70). Phospholipid metabolism is directly associated with cell growth since it provides membrane material for inner and outer hull structure. Still, it remains unclear whether this is the cause or just one of the consequences of reduced neuronal cell size and network connectivity of RTT. But as MECP2 basic function is global transcription dampener in combination with activity dependent activation of transcription this suggests that reduced membrane material production is a consequence of lack of activity specific transcription activation.

Table 3: Metabolites in RTT

Changes in RTT	Metabolites
Increased levels (65-67)	Catabolites of catecholamine metabolism, glutamate
Decreased levels (65-68)	Dopamine, norepinephrine (noradrenaline), serotonin, melatonin, myo-inositol, phospholipids, GABA

Genes/gene products

MECP2 is a global transcription and translation influencing factor but there are also single specific genes which are found to be up- or downregulated in the absence of functional MECP2. The expression of the MECP2 target genes is affected in human, mouse and *in vitro* models. In the absence of functional MECP2 the expression of [BDNF](#), [FKBP5](#), [IGF2](#), [DLX5](#), [DLX6](#), [SGK1](#), [GAMT](#), [FXD1](#) and [MPP1](#) is upregulated whereas the expression of [UBE3A](#) (15) and [GRID1](#) (71) are downregulated (Table 4 and see also the list on [wikipathways.org/instance/WP3584](http://www.wikipathways.org/instance/WP3584)). BDNF, which shows in all investigated models the most consistent effect, is a MECP2 regulated protein and it is necessary for neuronal development and function, too (Table 4). [BioGRID](#) is a biological repository for interaction data. In this repository, there are 156 unique interactors for (human) MECP2 registered and 11 for BDNF. The current complete list can be found online using these links for [MECP2](#) and [BDNF](#).

Table 4: Genes, which are up- or downregulated in human or model system without functional MECP2

Changes in RTT	Genes
Upregulated (15, 75)	BDNF, FKBP5, IGF2, DLX5, DLX6, SGK1, MPP1, GAMT, FXD1
Downregulated (15, 71)	UBE3A, GRID1

Pathways

Bedogni et al. mentioned the difficulty to identify unique target pathways of MECP2 because MECP2 is both a repressor and an activator of transcription and the balancing and timing of transcription levels seems to contribute more to disorder development than activation of single pathways (59). Several transcriptomics studies using samples from RTT females, mouse and *in vitro* model systems showed about 60 significantly enriched pathways, for example inflammation, MAPK signaling, ERBB signaling, neurotrophin intracellular cascade, sterol biosynthesis (76), cholesterol metabolism (76), cytoskeleton formation, and apoptosis (59).

While animal and *in vitro* models often use *MECP2* – KO models (e.g. *Mecp2*^{-/-} mouse) human RTT patient derived samples often have a residual MECP2 activity due to the various mutations which impair the function rather than inhibiting the expression completely. Tanaka et al. (64) investigated gene expression profile of iPSC lines derived from six different RTT females with different *MECP2* mutations. They created and compared expression profiles of two iPSCs cell lines derived from each of the patients, one with the X chromosome active that has the wild type *MECP2* and the other one with the

chromosome with the mutated gene. The differently expressed genes and altered pathways are very different for each patient. This is an interesting result, as there are so many different *MECP2* mutations which lead to RTT. A specific mutation affects protein function differently and may trigger different pathways leading to different phenotypes. Linking genetic data to molecular analysis (transcriptome, metabolome) and phenotype will be a future challenge to elucidate the pathways of RTT.

8 *MECP2*-related pathways involved in RTT phenotypes

In this chapter we discuss how mutated *MECP2* leads to failure in neuronal synapsis formation and function which are one of the major causes of RTT phenotype. *MECP2* acts in a biological network of constant interaction by regulating and being regulated. A phenotype is the final result of this complex network interaction.

According to Lyst and Bird (8) *MECP2* mutations cause RTT in two ways: 1. co-repressor recruitment, and 2. chromatin compaction, which are both basic molecular functions. Skene and Bedogni specified this assumption of *MECP2* function as a global dampener of transcription in neurons plus the activity dependent transcription activation which leads to proper synapsis function and development (32, 59).

The differences in global gene expression of RTT and wild-type control groups are not substantial – neither in fold change nor number of genes differently expressed - indicating that more subtle dysregulation events in several pathways are responsible for RTT (51, 77-80). *MECP2* is a global repressor of transcription (32), a global activator of gene translation (50) and it reacts on neuronal pathway signals which lead to phosphorylation of *MECP2* and detachment from DNA. Therefore, *MECP2* dampens neuronal transcription globally and allows activity related responses which seem to be necessary for learning activity and specific synapsis formation (81). Bedogni et al. found a direct connection between *MECP2* and pathways leading to cytoskeleton re-formation (59) indicating structural changes leading towards neuronal network formation. Li et al. found in human embryonic stem cells, which are developing from stem cells to neuronal precursor cells to neurons, that in a premature state, *MECP2* acts as an activator of transcription while transcription repressor activity was only found in mature neurons (50). The levels of *MECP2* start to increase postnatally and the protein is quite abundant in mature nervous systems (32, 82). The expression of *MECP2* is not uniform in different neuronal cell populations (83), parts of the brain and changes with age (84). Mouse *Mecp2*-KO neuronal precursor cells are not different from wildtype ones, they change only during maturation (82). Together with the observation that symptoms of RTT do not appear before about month 6, this led to the assumption that *MECP2* has less to do with neurogenesis but more with neuronal function and maintenance, and synapsis formation and function. This may explain why the RTT phenotype becomes visible only at the quite late age of 6-18 months. In RTT females brains a decreased number of synapsis was found (85-87). Synaptogenesis again is mostly observed in the period of RTT symptom development (month 6 – 18) which may explain the development of learning disability. In *MECP2* null mouse model reduced neuronal differentiation (88) and synaptic deficits (81) were observed. Mice studies and postmortem brains of RTT females reveal alterations in neuron structures which may be due to decreased dendritic complexity because of an immature synaptic spine morphology leading to malfunction of synaptic development and plasticity (89-91). Changed neuronal tubulin expression was

found directly in the brain tissue of RTT and Angelman syndrome patients (92). Dysfunctional MECP2 led also to changes in synaptic transmission, short and long-term synaptic plasticity, deficits in short and long term potentiation (LTP and LTD) in mice (93).

The abnormal levels of neurotransmitters and differently expressed neurotransmitter receptors lead to an imbalance between excitatory and inhibitory neuronal activity (namely imbalance of GABAergic, glutamatergic and dopaminergic neuronal pathways). Such abnormal ratio of excitation/inhibition in brain activity was also found in autistic patients before (94-96) and it is a known effect in Parkinson's disease which shares the motoric disabilities with RTT (97). RTT models using murine and human induced pluripotent stem cells showed some RTT features and these symptoms were documented for MECP2 overexpression models, too, leading again to the assumption that MECP2 function is dose dependent (16).

In summary, MECP2 affects epigenetic regulation of gene expression, which changes neurobiological activity, network formation and function, which causes the major phenotype. Although these processes could indeed explain many neuronal function related symptoms of RTT there is still lack of evidence for other phenotypes, especially those which occur in many but not in all RTT females. 1) Breathing patterns: breathing is regulated by brain stem function which gets its signals from receptors for blood pH, carbon dioxide and (to a lower amount) oxygen levels. Abnormal RTT breathing patterns could be caused by neuronal dysfunction of the brain stem or neuronal pathways but metabolic dysregulation involving abnormal creatin levels due to GAMT over/under expression is also an influencing factor (4). GAMT is one of the MECP2 downstream activated genes. 2) Cardiac abnormalities: heart beat is regulated by central nervous system but has its own nerve knots for signal production, too. Specialized neurons in the heart ensure proper electric signal transition. These might be affected by RTT directly, by brain stem function, or both. RTT patients are indeed known for higher incidence of heart problems. Furthermore, vascular dysfunctions have been found which are directly related to MECP2 dysfunction although the molecular pathway between MECP2 and effector genes is not yet elucidated (98). 3) Digestion and nutrient uptake problems: Stomach and intestines are covered with a complex network of nerve cells. Dysfunctional nerve cells may lead to constipation and malabsorption of nutrients, e.g. Vitamin D but there may also be other nutrient processing pathways involved. 4) Tissue specific effects: Tissue specific neuronal cells are differently influenced by MECP2 mutation, e.g. olfactory sensory vs. visual system (Table 5). Recently it was found that MECP2 mutations contribute to hypersensitivity of mechanoreceptors (99) which aligns with the observation of clinicians and caregivers. It is currently unknown in which neuronal cell subpopulations MECP2 is more or less necessary for normal function although there are indications that there are differences (83).

Table 5: Olfactory vs. visual system: tissue specific MECP2 influence

Olfactory epithelium	Visual system
The olfactory epithelium in postnatal rodents experiences strong upregulation of	Vertebrate eyes are originally specialized brain tissue. Though being expected to be subjected to MECP2

MECP2 (100, 101). MECP2 seems to regulate the activity dependent transcriptional responses in olfactory sensory neurons the same way as in central nervous system and model systems (102). This cycle of neuronal activity dependent transcription activation (fast feedback loop based on Ca^{2+}/calmodulin) seems to be responsible for neuronal circuitry refinement, playing a role in olfactory sensory nerve maturation and olfactory learning. MECP2 affects the expression of olfactory sensory cell adhesion molecules KIRREL2 and PCHD20 directly, KIRREL3, and CNTN4 indirectly. It represses KIRREL2 but is required for activity dependent upregulation of KIRREL2 after odor stimulation (102). KIRREL3 is an autism related gene (103) and the family of KIRREL genes is known to be widely expressed in neuronal tissue for synaptogenesis and synaptic specificity (104). MECP2 deficiency induces also an imbalance in glutamatergic/GABAergic innervation in the olfactory bulb. The excitation in MECP2 KO mice is reduced and there is generally an imbalance between excitatory and inhibitory pathways observed leading to premature death of olfactory neurons in RTT mice models (101). For humans, a study on olfactory bulb biopsies of RTT females revealed less olfactory receptors (105).	dysfunctionality symptoms the visual system, retina, visual nerve and visual cortex seem to be less affected by RTT. Patients are able to focus, blink, eye-track, and do not perform worse in visual tests than healthy population (106). Their families report often that they are using eye contact as communication method and therefore eye tracking systems are a promising method to improve communication. Jain et al. investigated ocular MECP2 expression in post mortem brains of RTT females and compared it to healthy controls. Although the RTT females suffer under the typical severe neurological deficits their visual functions are well preserved. There were no gross or microscopic aberrations detected and no significant MECP2 level differences (84). Another study investigating MECP2 expression levels in many neuronal and non-neuronal tissues found MECP2 to be expressed weak or moderate in the nucleoplasm of in retinal cells while there were peaks of strong MECP2 presence in chromocenters (107). Although it was shown in a previous study with MECP2 KO mice that their visual system (acuity) is affected with disorder onset (108) and visual systems also need refinement by circuits and MECP2 dependent synapse remodeling (109) this was not confirmed by the study of Song et al. (107). Their retina samples from MECP2 deficient mice did not show any differences to control concerning immunochemical markers, cellular and histological anatomy, synapsis formation and neurotransmitters (107). Together with the measured visual performance in human RTT females (106) these observations indicate that MECP2 surprisingly does not play a major role in ocular function.
Gap: Why is the olfactory sensory system affected in RTT females? Is there a measurable difference in response to olfactory stimulants?	Gap: What is the mechanistic explanation of the rather unaffected visual system?

To understand these processes integration of different levels of biological knowledge and research results is necessary and interactive biological pathways (such as wikipathways.org/instance/WP3584) help to organize, analyze, and visualize existing knowledge. To integrate the information the exact

mutation of MECP2 gene needs to be combined with molecular data (e.g. gene expression data, metabolomics) and a detailed description of the RTT females' phenotype (including clinical laboratory measurements). This process will increase the understanding of the underlying pathways of the variety of RTT phenotypes. Gathering this knowledge and bringing it properly together needs collaboration of biomedical and bioinformatics researchers, physicians and patients (110). Furthermore, knowing the essential pathways and their components which contribute to a certain phenotype or symptom may lead to the discovery of drug targets. These are not likely to be able to cure RTT itself but may help to reduce the severity of specific symptoms.

9 Conclusion

The present review summarizes the current knowledge about MECP2 structure and function, how it influences levels of metabolites, gene expression and biological pathways, and tries to bridge the different types of data available to explain the development of typical RTT phenotype by visualizing in form of a pathway (Figure 2 and online [wikipathways.org/instance/WP3584](http://www.wikipathways.org/instance/WP3584)). Although the dysregulation events in neuronal cells can be already explained quite well, the mechanistic explanation of several additional symptoms is still missing. Integrating the knowledge about the individual mutation, molecular data and phenotype information will help to find biological pathways and therefore explanations for these symptoms. Finding the right target genes, proteins, or metabolites can build a bridge between genotype and phenotype, and possibly to drug targets.

10 Acknowledgements

This work was funded by Stichting Terre – The Dutch Rett Syndrome Foundation.

11 Financial Disclosure

All authors report no biomedical financial interests or potential conflicts of interest.

12 References

1. Laurvick CL, de Klerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, et al. (2006): Rett syndrome in Australia: a review of the epidemiology. *J Pediatr.* 148:347-352.
2. Comission E (2009): Useful Information on Rare Diseases from an EU Perspective.
3. Rett A (1966): [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. *Wien Med Wochenschr.* 116:723-726.
4. Halbach NS, Smeets EE, Bierau J, Keularts IM, Plasqui G, Julu PO, et al. (2012): Altered carbon dioxide metabolism and creatine abnormalities in rett syndrome. *JIMD Rep.* 3:117-124.
5. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999): Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet.* 23:185-188.
6. Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. (2010): Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol.* 68:944-950.

7. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007): Reversal of neurological defects in a mouse model of Rett syndrome. *Science*. 315:1143-1147.
8. Lyst MJ, Bird A (2015): Rett syndrome: a complex disorder with simple roots. *Nat Rev Genet*. 16:261-275.
9. Katz DM, Bird A, Coenraads M, Gray SJ, Menon DU, Philpot BD, et al. (2016): Rett Syndrome: Crossing the Threshold to Clinical Translation. *Trends Neurosci*. 39:100-113.
10. Schwartzman JS, Velloso Rde L, D'Antino ME, Santos S (2015): The eye-tracking of social stimuli in patients with Rett syndrome and autism spectrum disorders: a pilot study. *Arq Neuropsiquiatr*. 73:402-407.
11. Oddy WH, Webb KG, Baikie G, Thompson SM, Reilly S, Fyfe SD, et al. (2007): Feeding experiences and growth status in a Rett syndrome population. *J Pediatr Gastroenterol Nutr*. 45:582-590.
12. Reilly S, Cass H (2001): Growth and nutrition in Rett syndrome. *Disabil Rehabil*. 23:118-128.
13. Guy J, Cheval H, Selfridge J, Bird A (2011): The role of MeCP2 in the brain. *Annu Rev Cell Dev Biol*. 27:631-652.
14. Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, Fontes M (2000): Two affected boys in a Rett syndrome family: clinical and molecular findings. *Neurology*. 55:1188-1193.
15. Bienvenu T, Chelly J (2006): Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. *Nat Rev Genet*. 7:415-426.
16. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, et al. (2004): Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. *Hum Mol Genet*. 13:2679-2689.
17. Liu J, Francke U (2006): Identification of cis-regulatory elements for MECP2 expression. *Hum Mol Genet*. 15:1769-1782.
18. Singh J, Saxena A, Christodoulou J, Ravine D (2008): MECP2 genomic structure and function: insights from ENCODE. *Nucleic Acids Res*. 36:6035-6047.
19. Liyanage VR, Rastegar M (2014): Rett syndrome and MeCP2. *Neuromolecular Med*. 16:231-264.
20. Newnham CM, Hall-Pogar T, Liang S, Wu J, Tian B, Hu J, et al. (2010): Alternative polyadenylation of MeCP2: Influence of cis-acting elements and trans-acting factors. *RNA Biol*. 7:361-372.
21. Burmistrova OA, Goltsov AY, Abramova LI, Kaleda VG, Orlova VA, Rogaev EI (2007): MicroRNA in schizophrenia: genetic and expression analysis of miR-130b (22q11). *Biochemistry (Mosc)*. 72:578-582.
22. Han K, Gennarino VA, Lee Y, Pang K, Hashimoto-Torii K, Choufani S, et al. (2013): Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p. *Genes Dev*. 27:485-490.
23. Guo Y, Chen Y, Carreon S, Qiang M (2012): Chronic intermittent ethanol exposure and its removal induce a different miRNA expression pattern in primary cortical neuronal cultures. *Alcohol Clin Exp Res*. 36:1058-1066.
24. Volkmann I, Kumarswamy R, Pfaff N, Fiedler J, Dangwal S, Holzmann A, et al. (2013): MicroRNA-mediated epigenetic silencing of sirtuin1 contributes to impaired angiogenic responses. *Circ Res*. 113:997-1003.
25. Lusardi TA, Farr CD, Faulkner CL, Pignataro G, Yang T, Lan J, et al. (2010): Ischemic preconditioning regulates expression of microRNAs and a predicted target, MeCP2, in mouse cortex. *J Cereb Blood Flow Metab*. 30:744-756.
26. Kriaucionis S, Bird A (2004): The major form of MeCP2 has a novel N-terminus generated by alternative splicing. *Nucleic Acids Res*. 32:1818-1823.
27. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, et al. (2004): A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. *Nat Genet*. 36:339-341.

28. Itoh M, Tahimic CG, Ide S, Otsuki A, Sasaoka T, Noguchi S, et al. (2012): Methyl CpG-binding protein isoform MeCP2_e2 is dispensable for Rett syndrome phenotypes but essential for embryo viability and placenta development. *J Biol Chem.* 287:13859-13867.
29. Adams VH, McBryant SJ, Wade PA, Woodcock CL, Hansen JC (2007): Intrinsic disorder and autonomous domain function in the multifunctional nuclear protein, MeCP2. *J Biol Chem.* 282:15057-15064.
30. Nan X, Campoy FJ, Bird A (1997): MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. *Cell.* 88:471-481.
31. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY (2002): Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. *Hum Mol Genet.* 11:115-124.
32. Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, et al. (2010): Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. *Mol Cell.* 37:457-468.
33. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, Bird AP (2005): DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. *Mol Cell.* 19:667-678.
34. Ballestar E, Yusufzai TM, Wolffe AP (2000): Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. *Biochemistry.* 39:7100-7106.
35. Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, et al. (2011): Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. *Hum Mol Genet.* 20:1182-1196.
36. Gonzales ML, Adams S, Dunaway KW, LaSalle JM (2012): Phosphorylation of distinct sites in MeCP2 modifies cofactor associations and the dynamics of transcriptional regulation. *Mol Cell Biol.* 32:2894-2903.
37. Long SW, Ooi JY, Yau PM, Jones PL (2011): A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. *Biosci Rep.* 31:333-343.
38. Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AB, Rose MF, et al. (2005): Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. *Proc Natl Acad Sci U S A.* 102:17551-17558.
39. Nomura T, Kimura M, Horii T, Morita S, Soejima H, Kudo S, et al. (2008): MeCP2-dependent repression of an imprinted miR-184 released by depolarization. *Hum Mol Genet.* 17:1192-1199.
40. Smith RM, Sadee W (2011): Synaptic signaling and aberrant RNA splicing in autism spectrum disorders. *Front Synaptic Neurosci.* 3:1.
41. Jaenisch R, Bird A (2003): Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet.* 33 Suppl:245-254.
42. Reik W, Dean W, Walter J (2001): Epigenetic reprogramming in mammalian development. *Science.* 293:1089-1093.
43. Fan G, Hutnick L (2005): Methyl-CpG binding proteins in the nervous system. *Cell Res.* 15:255-261.
44. Ehrlich M (2003): Expression of various genes is controlled by DNA methylation during mammalian development. *J Cell Biochem.* 88:899-910.
45. Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, et al. (2007): Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. *Nature.* 445:671-675.
46. Lyst MJ, Ekiert R, Ebert DH, Merusi C, Nowak J, Selfridge J, et al. (2013): Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. *Nat Neurosci.* 16:898-902.

47. Szulwach KE, Li X, Li Y, Song CX, Wu H, Dai Q, et al. (2011): 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. *Nat Neurosci.* 14:1607-1616.
48. Adkins NL, Georgel PT (2011): MeCP2: structure and function. *Biochem Cell Biol.* 89:1-11.
49. Nelson ED, Kavalali ET, Monteggia LM (2006): MeCP2-dependent transcriptional repression regulates excitatory neurotransmission. *Curr Biol.* 16:710-716.
50. Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Loven J, et al. (2013): Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. *Cell Stem Cell.* 13:446-458.
51. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. (2008): MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science.* 320:1224-1229.
52. Cartron PF, Nadaradjane A, Lepape F, Lalier L, Gardie B, Vallette FM (2013): Identification of TET1 Partners That Control Its DNA-Demethylating Function. *Genes Cancer.* 4:235-241.
53. Wang J, Tang J, Lai M, Zhang H (2014): 5-Hydroxymethylcytosine and disease. *Mutat Res Rev Mutat Res.* 762:167-175.
54. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. (2003): Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. *Science.* 302:885-889.
55. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, et al. (2006): Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. *Neuron.* 52:255-269.
56. Ebert DH, Greenberg ME (2013): Activity-dependent neuronal signalling and autism spectrum disorder. *Nature.* 493:327-337.
57. Tao J, Hu K, Chang Q, Wu H, Sherman NE, Martinowich K, et al. (2009): Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. *Proc Natl Acad Sci U S A.* 106:4882-4887.
58. Ebert DH, Gabel HW, Robinson ND, Kastan NR, Hu LS, Cohen S, et al. (2013): Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. *Nature.* 499:341-345.
59. Bedogni F, Rossi RL, Galli F, Cobolli Gigli C, Gandaglia A, Kilstrup-Nielsen C, et al. (2014): Rett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action. *Neurosci Biobehav Rev.* 46 Pt 2:187-201.
60. Lioy DT, Garg SK, Monaghan CE, Raber J, Foust KD, Kaspar BK, et al. (2011): A role for glia in the progression of Rett's syndrome. *Nature.* 475:497-500.
61. Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, Monteggia LM (2006): Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. *Biol Psychiatry.* 59:468-476.
62. Chao HT, Chen H, Samaco RC, Xue M, Chahrour M, Yoo J, et al. (2010): Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. *Nature.* 468:263-269.
63. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001): A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. *Nat Genet.* 27:322-326.
64. Tanaka Y, Kim KY, Zhong M, Pan X, Weissman SM, Park IH (2014): Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2). *Hum Mol Genet.* 23:1045-1055.
65. Lekman A, Witt-Engerstrom I, Gottfries J, Hagberg BA, Percy AK, Svennerholm L (1989): Rett syndrome: biogenic amines and metabolites in postmortem brain. *Pediatr Neurol.* 5:357-362.
66. Brucke T, Sofic E, Killian W, Rett A, Riederer P (1987): Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study. *J Neural Transm.* 68:315-324.
67. Panayotis N, Ghata A, Villard L, Roux JC (2011): Biogenic amines and their metabolites are differentially affected in the Mecp2-deficient mouse brain. *BMC Neurosci.* 12:47.

68. Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, Pena F, et al. (2005): Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. *J Neurosci.* 25:11521-11530.
69. Hutchinson AN, Deng JV, Aryal DK, Wetsel WC, West AE (2012): Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. *Neuropsychopharmacology.* 37:321-337.
70. Viola A, Saywell V, Villard L, Cozzone PJ, Lutz NW (2007): Metabolic fingerprints of altered brain growth, osmoregulation and neurotransmission in a Rett syndrome model. *PLoS One.* 2:e157.
71. Livide G, Patriarchi T, Amenduni M, Amabile S, Yasui D, Calcagno E, et al. (2015): GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells. *Eur J Hum Genet.* 23:195-201.
72. Johnston M, Blue ME, Naidu S (2015): Recent advances in understanding synaptic abnormalities in Rett syndrome. *F1000Res.* 4.
73. Ballas N, Liou DT, Grunseich C, Mandel G (2009): Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. *Nat Neurosci.* 12:311-317.
74. Naidu S, Kaufmann WE, Abrams MT, Pearlson GD, Lanham DC, Fredericksen KA, et al. (2001): Neuroimaging studies in Rett syndrome. *Brain Dev.* 23 Suppl 1:S62-71.
75. Deng V, Matagne V, Banine F, Frerking M, Ohliger P, Budden S, et al. (2007): FXD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. *Hum Mol Genet.* 16:640-650.
76. Lekman AY, Hagberg BA, Svennerholm LT (1991): Membrane cerebral lipids in Rett syndrome. *Pediatr Neurol.* 7:186-190.
77. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, Narayanan V, et al. (2001): Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. *Neurobiol Dis.* 8:847-865.
78. Nagarajan RP, Hogart AR, Gwyne Y, Martin MR, LaSalle JM (2006): Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. *Epigenetics.* 1:e1-11.
79. Tudor M, Akbarian S, Chen RZ, Jaenisch R (2002): Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. *Proc Natl Acad Sci U S A.* 99:15536-15541.
80. Ben-Shachar S, Chahrour M, Thaller C, Shaw CA, Zoghbi HY (2009): Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. *Hum Mol Genet.* 18:2431-2442.
81. Monteggia LM, Kavalali ET (2009): Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. *Biol Psychiatry.* 65:204-210.
82. Kishi N, Macklis JD (2004): MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. *Mol Cell Neurosci.* 27:306-321.
83. Sugino K, Hempel CM, Okaty BW, Arnson HA, Kato S, Dani VS, et al. (2014): Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes. *J Neurosci.* 34:12877-12883.
84. Jain D, Singh K, Chirumamilla S, Bibat GM, Blue ME, Naidu SR, et al. (2010): Ocular MECP2 protein expression in patients with and without Rett syndrome. *Pediatr Neurol.* 43:35-40.
85. Belichenko PV, Wright EE, Belichenko NP, Masliah E, Li HH, Mobley WC, et al. (2009): Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. *J Comp Neurol.* 514:240-258.
86. Matarazzo V, Cohen D, Palmer AM, Simpson PJ, Khokhar B, Pan SJ, et al. (2004): The transcriptional repressor Mecp2 regulates terminal neuronal differentiation. *Mol Cell Neurosci.* 27:44-58.
87. Palmer A, Qayumi J, Ronnett G (2008): MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively. *Mol Cell Neurosci.* 37:794-807.

88. Zhao X, Ueba T, Christie BR, Barkho B, McConnell MJ, Nakashima K, et al. (2003): Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. *Proc Natl Acad Sci U S A*. 100:6777-6782.
89. Kaufmann WE, Moser HW (2000): Dendritic anomalies in disorders associated with mental retardation. *Cereb Cortex*. 10:981-991.
90. Jugloff DG, Jung BP, Purushotham D, Logan R, Eubanks JH (2005): Increased dendritic complexity and axonal length in cultured mouse cortical neurons overexpressing methyl-CpG-binding protein MeCP2. *Neurobiol Dis*. 19:18-27.
91. Francke U (2006): Mechanisms of disease: neurogenetics of MeCP2 deficiency. *Nat Clin Pract Neurol*. 2:212-221.
92. Abuhatzira L, Shemer R, Razin A (2009): MeCP2 involvement in the regulation of neuronal alpha-tubulin production. *Hum Mol Genet*. 18:1415-1423.
93. Asaka Y, Jugloff DG, Zhang L, Eubanks JH, Fitzsimonds RM (2006): Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. *Neurobiol Dis*. 21:217-227.
94. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J (2001): Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. *Neurology*. 57:1618-1628.
95. Rubenstein JL, Merzenich MM (2003): Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav*. 2:255-267.
96. Serajee FJ, Zhong H, Nabi R, Huq AH (2003): The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism. *J Med Genet*. 40:e42.
97. di Michele F, Luchetti S, Bernardi G, Romeo E, Longone P (2013): Neurosteroid and neurotransmitter alterations in Parkinson's disease. *Front Neuroendocrinol*. 34:132-142.
98. Panighini A, Duranti E, Santini F, Maffei M, Pizzorusso T, Funel N, et al. (2013): Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment. *PLoS One*. 8:e64863.
99. Orefice LL, Zimmerman AL, Chirila AM, Sleboda SJ, Head JP, Ginty DD (2016): Peripheral Mechanosensory Neuron Dysfunction Underlies Tactile and Behavioral Deficits in Mouse Models of ASDs. *Cell*.
100. Cohen DR, Matarazzo V, Palmer AM, Tu Y, Jeon OH, Pevsner J, et al. (2003): Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis. *Mol Cell Neurosci*. 22:417-429.
101. Degano AL, Park MJ, Penati J, Li Q, Ronnett GV (2014): MeCP2 is required for activity-dependent refinement of olfactory circuits. *Mol Cell Neurosci*. 59:63-75.
102. Lee W, Yun JM, Woods R, Dunaway K, Yasui DH, Lasalle JM, et al. (2014): MeCP2 regulates activity-dependent transcriptional responses in olfactory sensory neurons. *Hum Mol Genet*. 23:6366-6374.
103. Talkowski ME, Rosenfeld JA, Blumenthal I, Pillalamarri V, Chiang C, Heilbut A, et al. (2012): Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. *Cell*. 149:525-537.
104. Shen K, Fetter RD, Bargmann CI (2004): Synaptic specificity is generated by the synaptic guidepost protein SYG-2 and its receptor, SYG-1. *Cell*. 116:869-881.
105. Ronnett GV, Leopold D, Cai X, Hoffbuhr KC, Moses L, Hoffman EP, et al. (2003): Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. *Ann Neurol*. 54:206-218.
106. Saunders KJ, McCulloch DL, Kerr AM (1995): Visual function in Rett syndrome. *Dev Med Child Neurol*. 37:496-504.
107. Song C, Feodorova Y, Guy J, Peichl L, Jost KL, Kimura H, et al. (2014): DNA methylation reader MECP2: cell type- and differentiation stage-specific protein distribution. *Epigenetics Chromatin*. 7:17.

108. Durand S, Patrizi A, Quast KB, Hachigian L, Pavlyuk R, Saxena A, et al. (2012): NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. *Neuron*. 76:1078-1090.
109. Noutel J, Hong YK, Leu B, Kang E, Chen C (2011): Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. *Neuron*. 70:35-42.
110. Townend GS, van Kranen HJ, van der Stel R, van den Berg M, Smeets E, van Waardenburg D, et al. (2015): Rett Syndrome as a Rare Disease: A European Perspective. *Public Health Genomics*. 18:233-236.